Recent news on Invanz

Merck Reports Strong Financial Results for First-Quarter 2007  -  Apr 19, 2007
Business Wire (press release),Other reported products comprise: AGGRASTAT, ARCOXIA, CANCIDAS, COSOPT, CRIXIVAN, EMEND, INVANZ, JANUVIA, MAXALT, PRIMAXIN, PROPECIA, PROSCAR, STOCRIN,

Merck to start clinical trial of new drugs  -  Apr 1, 2007
Business Standard,It is also planning to introduce three more drugs — Cosopt, Invanz and Pneuvax— worth over $650 million by global sales, in India in the coming months.

Merck to roll out money-spinning drugs soon  -  Mar 18, 2007
Therapeutics Daily (subscription) (press release),Invanz, the drug used to treat community-acquired pneumonia, enjoys international sales worth $150 million. Pneuvax-23, a pneumococcal vaccine,

Pediatric studies lead to more information on drug labels  -  Feb 1, 2007
AAP News (subscription)Invanz (ertapenem) is indicated for the treatment of serious infections, including complicated intra-abdominal infections, complicated skin infections,

Merck Announces 2006 Financial Results that Demonstrate Solid ...  -  Jan 30, 2007
Business Wire (press release),COSOPT, CRIXIVAN, EMEND, INVANZ, JANUVIA, MAXALT, PRIMAXIN, PROPECIA, PROSCAR, STOCRIN, TIMOPTIC/TIMOPTIC XE, TRUSOPT, VASOTEC/VASERETIC and ZOLINZA.

FDA Approves New Indication For INVANZ® (ertapenem) For The ...  -  18 Jan 2007
Medical News Today (press release),Inc. In the PREVENT study, a statistically significant difference favoring INVANZ over cefotetan with respect to the primary endpoint has been observed.

Merck's Invanz Gets New FDA Approval  -  18 Jan 2007
Forbes,Drug developer Merck & Co. said Wednesday the Food and Drug Administration approved the company's Invanz for the additional use as a preventative treatment

Invanz Prophylaxis Outperforms Cefotan in Colorectal Surgery  -  Dec 20, 2006
MedPage Today,Note that this study suggests that in colorectal surgery Invanz (ertapenem) works better than Cefotan (cefotetan), which has been the recommended

Merck Invanz OK'd to stop postop infection  -  Dec 20, 2006
United Press International20 (UPI) -- US firm Merck said Wednesday it got approval for a new use for its drug Invanz to prevent surgical site infections after colorectal surgery.

Merck antibiotic gets FDA nod for additional use  -  Dec 20, 2006
ReutersN: Quote, Profile , Research) said on Wednesday that US health regulators have approved the expanded use of the company's injectable antibiotic Invanz for

Stocks to Watch, Dec. 21: Red Hat  -  Dec 20, 2006
FOX News...(MRK) said the Food and Drug Administration approved Invanz, an injectable antibiotic, for the prevention of surgical site infections after elective

Merck's Invanz gets new FDA approval  -  Dec 20, 2006
BusinessWeek...said Wednesday the Food and Drug Administration approved the company's Invanz for the additional use as a preventative treatment of surgical site infection. ...

Merck Invanz OK'd to stop postop infection  -  Dec 20, 2006
United Press International20 (UPI) -- US firm Merck said Wednesday it got approval for a new use for its drug Invanz to prevent surgical site infections after colorectal surgery. ...

Invanz Prophylaxis Outperforms Cefotan in Colorectal Surgery  -  Dec 20, 2006
MedPage Today,20 -- The long-acting antibiotic Invanz (ertapenem) appears to be superior to Cefotan (cefotetan), which has been the recommended antibiotic for prophylaxis in ...

REPEAT/FDA Approves New Indication for INVANZ ® (ertapenem) for ...  -  Dec 21, 2006
Business Wire (press release),...announced today that the US Food and Drug Administration (FDA) recently approved INVANZ ® (ertapenem), a once-daily injectable antibiotic, for the prophylaxis ...

Merck antibiotic gets FDA nod for additional use  -  Dec 20, 2006
ReutersN: Quote, Profile , Research) said on Wednesday that US health regulators have approved the expanded use of the company's injectable antibiotic Invanz for the ...

Stocks to Watch, Dec. 21: Red Hat  -  Dec 20, 2006
FOX NewsMerck & Co. (MRK) said the Food and Drug Administration approved Invanz, an injectable antibiotic, for the prevention of surgical site infections after ...

Merck Remains Confident in Future Growth as it Executes on New ...  -  Dec 12, 2006
Genetic Engineering News (press release),Other reported products comprise: AGGRASTAT, ARCOXIA, CANCIDAS, COSOPT, CRIXIVAN, EMEND, INVANZ, MAXALT, PRIMAXIN, PROPECIA, PROSCAR, STOCRIN, TIMOPTIC ...

Merck & Co: broadening the anti-infective portfolio  Nov 2, 2006
The company has a broad anti-infective portfolio covering HIV drugs (protease inhibitor Crixivan), antibiotics (Invanz and Primaxin) and antifungals (Cancidas ... -Pharmaceutical Business Review Publicado: Sab Oct 14, 2006 5:01 pm Asunto: Unless directed to do ...  Oct 14, 2006
I had alwa insulin s had an interest in herbs and natural medicine, as did ou inulin friends, so I told her to try modifying Jims diet invanz and then we could ... -Shell Security, Merck Announces Strong Financial Results for the Third Quarter ...  Oct 20, 2006
Other reported products comprise: AGGRASTAT, ARCOXIA, CANCIDAS, COSOPT, CRIXIVAN, EMEND, INVANZ, MAXALT, PRIMAXIN, PROPECIA, PROSCAR, STOCRIN, TIMOPTIC ... -Business Wire (press release), Merck Remains Confident in Future Growth as it Executes on New ...  -  12 Dec 2006
Genetic Engineering News (press release),Other reported products comprise: AGGRASTAT, ARCOXIA, CANCIDAS, COSOPT, CRIXIVAN, EMEND, INVANZ, MAXALT, PRIMAXIN, PROPECIA, PROSCAR, STOCRIN,

Committee for Medicinal Products for Human Use Post-authorisation ...  Jul 28, 2006
Products for Human Use (CHMP) adopted a positive opinion to recommend the variation to the terms of the marketing authorisation for the medicinal product Invanz ... -PharmaLive.com

EU Expert Panel: Positive Opinion On Sanofi's Gardasil -3  Jul 28, 2006
The panel also issued a positive opinion on the extension of indications for Invanz, from Merck, to extend its indication to add prophylaxis of surgical site ... -Easy Bourse (Communiqués de presse)



Merck Announces Strong Financial Results for the First Quarter ...  Apr 20, 2006
...reported products* $6.3 to $6.6 billion * Other reported products comprise: AGGRASTAT, ARCOXIA, CANCIDAS, COSOPT, CRIXIVAN, EMEND, INVANZ, MAXALT, PRIMAXIN ... - Business Wire





Merck and Paratek Pharmaceuticals Sign Collaboration Agreement for ...  Mar 9, 2006
...of Merck that we found very compelling, in addition to their strong current presence in the hospital anti-infectives market with CANCIDAS(R), INVANZ(R), and ... - Genetic Engineering News

Merck Allies to Develop New Antibiotics  Mar 9, 2006
...amid growing incidences of resistance to antibiotics. Merck currently markets the anti-infectives Cancidas, Invanz and Primaxin. - Business New Jersey (subscription)

Merck and Paratek Pharmaceuticals Sign Collaboration Agreement for ...  Mar 9, 2006
...side of Merckthat we found very compelling, in addition to their strong currentpresence in the hospital anti-infectives market with CANCIDAS(R),INVANZ(R), and ... - Finanzen.net

Merck and Paratek Pharmaceuticals Sign Collaboration Agreement for ...  Mar 9, 2006
Merck that we found very compelling, in addition to their strong current presence in the hospital anti-infectives market with CANCIDAS®, INVANZ®, and PRIMAXIN ... - PharmaLive.com

Merck Announces Strong Full-Year and Fourth-Quarter 2005 Earnings ...  Jan 31, 2006
Merck announced in November that the FDA has approved INVANZ, a once-daily injectable antibiotic, for the treatment of moderate to severe complicated foot ... - TMCnet

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional